

MolMed Shareholders' Meeting approves the Financial Statements 2013

Milan (Italy), 8 April 2014 – The Shareholders' Meeting of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, met today to resolve upon the items of the agenda:

Item 1: approval of the Statutory Financial Statements for year 2013

The Meeting approved the Statutory Financial Statements for FY ended 31 December 2013, which recorded an overall loss of € 18.2 million. Following the resolution of the extraordinary Shareholders' Meeting of 3 March 2014, the loss is already covered for € 17.3 million; today's Meeting approved the proposal to carry forward the remaining loss of € 0.8 million.

The approved Statutory Financial Statements report a loss which is in line with expectations for the period and reflects the business model of a biotech company focused on R&D activities whose economic return is deferred to future years. The approved Financial Statements report a positive net financial position of € 7.5 million, consisting primarily of cash.

Item 2: resolution on Section I of the Report on remuneration

The Meeting expressed a favourable advisory opinion on the contents of Section I of the annual Report on the remuneration policy, with specific reference to its programmatic contents and to the procedures used for adopting and implementing this policy.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

For further information:

Marina Del Bue

General Manager Business & Administration

Investor Relations Director *ad int.*

MolMed S.p.A.

phone: +39 02 21277.371

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Andrea Quaglino

Director of Administration, Finance and Control

MolMed S.p.A.

phone: +39 02 21277.302

fax: +39 02 21277.404

e-mail: afc@molmed.com

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milano, Italy | Phone+39 0221277.1 - Fax +39 02 21277.325

info@molmed.com - www.molmed.com

Share capital € 10,861,168.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



PRESS RELEASE

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.